Phase III Trial Confirms Safety of Novartis’ Gilenya

A few days after confirming that a patient died 24 hours after beginning treatment with Gilenya, Novartis today announced positive data from an additional major late-stage study of their multiple sclerosis drug. Results from the 1, 083-patient Phase III 2309 trial revealed that sufferers with relapsing-remitting multiple sclerosis (MS) treated with Gilenya (fingolimod) had a

Continue Reading